Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells

Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

(2019) Amy S. Clark et al.   CLINICAL CANCER RESEARCH

Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer

(2019) Joan Cao et al.   ONCOGENE

Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways

(2018) Claudia Fumarola et al.   BIOCHEMICAL PHARMACOLOGY

Update on the Treatment of Early-Stage Triple-Negative Breast Cancer

(2018) Priyanka Sharma   CURRENT TREATMENT OPTIONS IN ONCOLOGY

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

(2018) Daniele Cretella et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

(2018) Neil O'Brien et al.   MOLECULAR CANCER THERAPEUTICS

Response evaluation with 18F-FDG PET/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice

(2018) Silvia Taralli et al.   ANNALS OF NUCLEAR MEDICINE

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

(2018) Francesco Schettini et al.   Frontiers in Oncology

CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest

(2017) Ashleigh M. Francis et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss

(2017) Yan Gao et al.   CELLULAR ONCOLOGY

Targeting the RB-E2F pathway in breast cancer

(2016) J Johnson et al.   ONCOGENE

Progress with palbociclib in breast cancer: latest evidence and clinical considerations

(2016) Andrea Rocca et al.   Therapeutic Advances in Medical Oncology

Fundamentals of cancer metabolism

(2016) R. J. DeBerardinis et al.   Science Advances

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

(2015) Go J. Yoshida   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

(2014) Daniele Cretella et al.   Molecular Cancer

Inhibitor of MYC identified in a Krohnke pyridine library

(2014) J. R. Hart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer

(2013) Sheng Zhang et al.   TUMOR BIOLOGY

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

Re-thinking cell cycle regulators: the cross-talk with metabolism

(2013) Lluis Fajas   Frontiers in Oncology

Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4

(2012) X. Huang et al.   BLOOD

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

(2012) A. Kathleen McClendon et al.   CELL CYCLE

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

(2012) Jeffry L. Dean et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myc Posttranscriptionally Induces HIF1 Protein and Target Gene Expression in Normal and Cancer Cells

(2011) M. R. Doe et al.   CANCER RESEARCH

Examining the role of cyclin D1 in breast cancer

(2011) Marco A Velasco-Velázquez et al.   Future Oncology

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

(2011) Roberta R Alfieri et al.   Molecular Cancer

Synergistic activity of letrozole and sorafenib on breast cancer cells

(2010) Mara A. Bonelli et al.   BREAST CANCER RESEARCH AND TREATMENT

Metabolism and proliferation share common regulatory pathways in cancer cells

(2010) V Fritz et al.   ONCOGENE

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Akt and c-Myc Differentially Activate Cellular Metabolic Programs and Prime Cells to Bioenergetic Inhibition

(2009) Yongjun Fan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

(2008) A. Cavazzoni et al.   MOLECULAR CANCER THERAPEUTICS

A role for Myc in facilitating transcription activation by E2F1

(2008) J Y Leung et al.   ONCOGENE